Your shopping cart is currently empty

J-2156 TFA is a selective SST4 receptor (somatostatin receptor type 4) agonist with IC50 values of 0.05 nM and 0.07 nM for human and rat SST4 receptors respectively. It exhibits anti-inflammatory and analgesic effects while reducing pERK levels.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $64 | - | In Stock | |
| 5 mg | Preferential | - | In Stock |
| Description | J-2156 TFA is a selective SST4 receptor (somatostatin receptor type 4) agonist with IC50 values of 0.05 nM and 0.07 nM for human and rat SST4 receptors respectively. It exhibits anti-inflammatory and analgesic effects while reducing pERK levels. |
| Targets&IC50 | SST4 (human):0.05 nM, SST4 (rat):0.07 nM |
| In vitro | J-2156 TFA exhibits nanomolar affinity (Ki=1.2 nM) for the homo sapiens somatostatin receptor subtype 4 (hsst4), with over 400-fold selectivity for this subtype compared to other somatostatin receptors [2]. |
| In vivo | J-2156 TFA (1-10 mg/kg, 3 hours) was administered as a single intraperitoneal injection, which produced anti-parazacco spilurus subsp. spilurus chronic pain effects in both ipsilateral and contralateral sides of BCIBP rats [1]. |
| Synonyms | J2156 TFA, J 2156 TFA |
| Molecular Weight | 582.6 |
| Formula | C26H29F3N4O6S |
| Cas No. | 2387505-73-7 |
| Smiles | OC(=O)C(F)(F)F.Cc1ccc(c2ccccc12)S(=O)(=O)N[C@@H](CCN)C(=O)N[C@@H](Cc1ccccc1)C(N)=O |
| Storage | keep away from moisture,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: 80 mg/mL (137.32 mM), Sonication is recommended. DMSO: 80 mg/mL (137.32 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (5.66 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O/DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.